3 Undervalued Biotechnology Stocks for Wednesday, November 13
Discover the top 3 undervalued Biotechnology stocks for Wednesday, November 13 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Commentary & Analysis
4 Undervalued Pharmaceuticals Stocks for Wednesday, September 04
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, September 04 based on AAII’s Stock Grades.Jenna Brashear
6 Undervalued Pharmaceuticals Stocks for Thursday, July 25
Discover the top 6 undervalued Pharmaceuticals stocks for Thursday, July 25 based on AAII’s Stock Grades.Jenna Brashear
6 Undervalued Pharmaceuticals Stocks for Tuesday, April 16
Discover the top 6 undervalued Pharmaceuticals stocks for Tuesday, April 16 based on AAII’s Stock Grades.Grace Malone
4 Undervalued Pharmaceuticals Stocks for Friday, March 08
Discover the top 4 undervalued Pharmaceuticals stocks for Friday, March 08 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | PMCB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.2 | $252.6 | 5% |
|
| Shares Out (Mil) | 10.7 | 52.3 | 21% |
|
| Institutional Ownership | 58.1% | 92.1% | 38% |
|
| Float (Mil) | 10.0 | 40.2 | 19% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 164 | 455 | 42% |
|
| Price Change (52-week) |
(43.8%) | 52.9% | 18% |
|
| Growth | PMCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (40.1%) | (9.9%) | 9% |
|
| EPS (5yr) | (2.5%) | 16.0% | 27 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.6%) | (15.6%) | 55% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PMCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($19) | ($43) | 24% |
|
| EPS (TTM) | ($2.770) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($31) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($30) | $180 | 1% |
|
| Valuation | PMCB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.18 | 2.56 | 3% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PMCB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (38.1%) | (49.8%) | 14% |
|
| ROE | (45.4%) | (55.5%) | 16% |
|
| Liabilities to Assets | 25.2% | 30.3% | 17% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 0.7% |
| +/- S&P 500: | -6.8 |
